SCHEMBL6099009

SCHEMBL6099009

[c]1ccc(-c2cccc(Oc3ccccc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.48
FFAR1 O14842 2/20 0.48
MAOB P27338 1/20 0.47
LTA4H P09960 1/20 0.46
TSHR P16473 1/20 0.46
GSTP1 P09211 1/20 0.44
AKR1C3 P42330 1/20 0.43
GAA P10253 3/20 0.40
MEN1 O00255 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NLRP1 Q9C000 1/20 0.39
NOD2 Q9HC29 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2261470 0.96 FFAR4 (0.48) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL4536542 0.88 LTA4H (0.60) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL11817040 0.86 LTA4H (0.57) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL30731588 0.86 LTA4H (0.57) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL10622416 0.86 LTA4H (0.57) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL27601568 0.86 FFAR4 (0.58) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL2879014 0.85 LTA4H (0.63) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL16361075 0.85 LTA4H (0.55) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL19845792 0.84 LTA4H (0.55) FFAR4FFAR1MAOBLTA4HTSHR
SCHEMBL19891793 0.84 FFAR4 (0.61) FFAR4FFAR1MAOBLTA4HTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122580-B2 Aryl and heteroaryl compounds and methods to modulate coagulation TRANSTECH PHARMA, INC. (US) 2006-10-17 US claimed
EP-1546089-A2 ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION TransTech Pharma Inc. (US) 2005-06-29 EP claimed
US-20040110832-A1 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc TRANSTECH PHARMA, LLC 2004-06-10 US claimed
WO-2004014844-A2 ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION TRANSTECH PHARMA, INC. (US) 2004-02-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110832-A1 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc TFPI, F9, TFPI2 FFAR4 1195/4885FFAR1 1569/4885MAOB 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.